Home ▸ News Release ▸ Preoperative Dual Immunotherapy Combination Shows Promising Activity in High-Risk Early-Stage HER2-Negative Breast CancerPreoperative Dual Immunotherapy Combination Shows Promising Activity in High-Risk Early-Stage HER2-Negative Breast CancerPosted in News Release | Tagged breast cancer, breast cancer research, cancer, clinical trials, immunotherapyMedia Contact Karen Teberkm463@georgetown.eduWASHINGTON (July 30, 2026) — A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform. Claudine Isaacs, MDHER2 breast cancer is also referenced as ERBB2 breast cancer; ERBB2 is the name of the gene, and HER2 (Human Epidermal growth factor Receptor 2) is the protein it creates. In triple-negative breast cancer, pCR rates increased from 29% to 53%. People with positive ImPrint results receiving PCF had notably high pCR rates, including 83% in triple-negative breast cancer and 91% in hormone receptor-positive/HER2-negative disease. Regeneron and Amgen provided funding and study drugs but had no role in the study’s design, conduct, analysis or reporting.